Rigel Pharmaceuticals (RIGL) Receivables - Net (2016 - 2025)
Rigel Pharmaceuticals (RIGL) has 12 years of Receivables - Net data on record, last reported at $51.8 million in Q4 2025.
- For Q4 2025, Receivables - Net rose 24.39% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $51.8 million, up 24.39%, while the annual FY2025 figure was $51.8 million, 24.39% up from the prior year.
- Receivables - Net reached $51.8 million in Q4 2025 per RIGL's latest filing, up from $45.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $142.2 million in Q1 2021 and bottomed at $3.0 million in Q1 2025.
- Average Receivables - Net over 5 years is $31.6 million, with a median of $25.5 million recorded in 2023.
- Peak YoY movement for Receivables - Net: surged 1372.0% in 2021, then tumbled 89.28% in 2022.
- A 5-year view of Receivables - Net shows it stood at $15.5 million in 2021, then rose by 29.27% to $20.0 million in 2022, then skyrocketed by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then grew by 24.39% to $51.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $51.8 million in Q4 2025, $45.9 million in Q3 2025, and $39.9 million in Q2 2025.